Stock futures dipped on Thursday as investors weighed President Trump’s 90-day tariff reprieve for select countries, which ...

DexCom DXCM underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing ...

The S&P 500 Index ($SPX) (SPY) today is down -3.05%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -2.52%, and the ...

The S&P 500 Index ($SPX) (SPY) today is down -2.50%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -2.05%, and the ...

Dexcom (Nadsaq:DXCM) announced today that the FDA cleared its G7 15-day continuous glucose monitoring (CGM) system.

The San Diego-based medical device company stated that the Dexcom G7 15 Day has an overall Mean Absolute Relative Difference (MARD) of 8.0%, showcasing its precision in glucose level readings. The ...

Mizuho analyst Anthony Petrone initiated coverage of DexCom (DXCM) with an Outperform rating and $85 price target The firm cites its positive ...

DexCom (NasdaqGS:DXCM) experienced an 12% decline over the past week, during which the company transitioned its audit from Ernst & Young to Deloitte & Touche, and appointed Jon Coleman as Chief ...

DexCom Inc. closed 52.68% below its 52-week high of $141.25, which the company reached on April 11th.

Dexcom advanced the launch of Stelo, its over-the-counter product for non-insulin type 2 diabetes, pre-diabetes, and ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Dexcom (DXCM – Research Report), with a price ...

Despite these developments, the broader market turbulence, marked by a steep drop in major indices due to tariff concerns, likely compounded the pressure on DXCM's share price. The general market ...